Effect of trastuzumab combined with endocrine therapy on hormone receptor and human epidermal growth factor receptor-2 positive advanced breast cancer
10.3760/cma.j.issn.1008-6706.2018.11.017
- VernacularTitle: 曲妥珠单抗联合三苯氧胺治疗雌激素受体及人表皮生长因子受体2阳性晚期乳腺癌的效果观察
- Author:
Zejun SONG
1
Author Information
1. Department of Oncology, Laiyang Central Hospital, Yantai, Shandong 265200, China
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Receptors, estrogen;
Receptor, epidermal growth factor;
Trastuzumab
- From:
Chinese Journal of Primary Medicine and Pharmacy
2018;25(11):1424-1427
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of trastuzumab combined with endocrine therapy on hormone receptor (HR) and human epidermal growth factor receptor-2 (HER-2) positive advanced breast cancer.
Methods:From January 2001 to March 2017, 88 patients with HR and HER-2 positive advanced breast cancer were selected.The patients were divided into two groups according to the random number method, with 44 cases in each group.All the patients were treated with routine chemotherapy, radiotherapy and biology therapy.The control group was treated with tamoxifen, and the observation group was treated with trastuzumab on the basis of the control group.All the patients were followed up for 6 months.The changes of serum E2 and quality of life were compared before and after intervention.The clinical effects of the two groups were compared.
Results:The serum E2 of the observation group was (15.3±0.5)pmol/L, which was lower than that before intervention [(65.4±2.0)pmol/L]and that of the control group after treatment [(36.9±1.9)pmol/L](t=70.109, 0.240, all P<0.05). After the intervention, the quality of life score of the observation group was (35.3±1.1)points, which was higher than that before intervention[(81.5±2.3)points]and that of the control group after treatment [(56.6±1.7)points](t=114.608, 66.530, all P<0.05). The effective rate of the observation group was 31.8%, which was higher than 9.1% of the control group (χ2=5.657, P<0.05).
Conclusion:Trastuzumab combined with endocrine maintenance therapy can effectively regulate the endocrine level of patients with HR and HER-2 positive advanced breast cancer, improve the quality of life and clinical therapeutic effect.
